MCID: PRS021
MIFTS: 51

Prostatic Adenoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostatic Adenoma

MalaCards integrated aliases for Prostatic Adenoma:

Name: Prostatic Adenoma 12 54 15 71
Prostatic Hyperplasia 43 71
Benign Prostatic Hyperplasia 71
Benign Adenoma of Prostate 12
Adenoma of Prostate 12
Adenoma - Prostate 12
Prostate Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2883
MeSH 43 D011470
NCIt 49 C4795
SNOMED-CT 67 21173002
UMLS 71 C0520477 C1704272 C2937421

Summaries for Prostatic Adenoma

Disease Ontology : 12 A male reproductive organ benign neoplasm that derives from glandular epithelial cells and that is located in the prostate.

MalaCards based summary : Prostatic Adenoma, also known as prostatic hyperplasia, is related to prostatic hyperplasia, benign and androgenic alopecia, and has symptoms including prostatism An important gene associated with Prostatic Adenoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Selegiline and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and bone, and related phenotypes are Decreased substrate adherent cell growth and behavior/neurological

Related Diseases for Prostatic Adenoma

Diseases related to Prostatic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 316)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 31.1 SRD5A1 SERPINA3 KLK3
2 androgenic alopecia 30.7 SRD5A1 KLK3
3 impotence 30.6 SRD5A1 KLK3 ADRA2C ADRA1D ADRA1B ADRA1A
4 urethral stricture 30.5 KLK3 ADRA1D
5 prostatic hypertrophy 30.4 SRD5A1 SERPINA3 KLK3 ADRA1D ADRA1A
6 prostate disease 29.7 SRD5A1 SERPINA3 KLK3
7 congestive heart failure 28.9 ADRB2 ADRB1 ADRA2C
8 sexual disorder 28.6 KLK3 ADRB3 ADRB1 ADRA2C ADRA2B ADRA2A
9 body mass index quantitative trait locus 11 28.6 SERPINA3 ADRB3 ADRB2 ADRB1 ADRA2A
10 hypertension, essential 27.0 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
11 pain agnosia 26.7 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
12 benign prostate phyllodes tumor 11.3
13 adenoma 11.2
14 prostatitis 10.5
15 pure autonomic failure 10.5
16 overgrowth syndrome 10.5
17 body mass index quantitative trait locus 1 10.4
18 suppression of tumorigenicity 12 10.4
19 pachyonychia congenita 3 10.3
20 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
21 neurogenic bladder 10.3
22 alopecia 10.3
23 insulin-like growth factor i 10.3
24 hyperinsulinism 10.3
25 b-cell lymphoma 10.3
26 aging 10.3
27 infant gynecomastia 10.3
28 gynecomastia 10.3
29 dopamine beta-hydroxylase deficiency 10.2 ADRA2C ADRA1B
30 48,xyyy 10.2
31 pyelonephritis 10.2
32 mycobacterium tuberculosis 1 10.2
33 cystitis 10.2
34 chronic kidney disease 10.2
35 syncope 10.2
36 pik3ca-related overgrowth syndrome 10.2
37 ureterolithiasis 10.2 ADRA1D ADRA1A
38 sex development disorder 10.2 SRD5A1 KLK3
39 alopecia, androgenetic, 1 10.2
40 proteasome-associated autoinflammatory syndrome 1 10.2
41 varicocele 10.2
42 inguinal hernia 10.1
43 non-alcoholic fatty liver disease 10.1
44 liver disease 10.1
45 liver cirrhosis 10.1
46 diabetes mellitus 10.1
47 fatty liver disease 10.1
48 cytokine deficiency 10.1
49 horner's syndrome 10.1 ADRA2A ADRA1A
50 breast cyst 10.1 SERPINA3 KLK3

Graphical network of the top 20 diseases related to Prostatic Adenoma:



Diseases related to Prostatic Adenoma

Symptoms & Phenotypes for Prostatic Adenoma

UMLS symptoms related to Prostatic Adenoma:


prostatism

GenomeRNAi Phenotypes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 8.92 ADRA1A ADRA1B ADRA1D ADRA2B

MGI Mouse Phenotypes related to Prostatic Adenoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C
2 cardiovascular system MP:0005385 9.56 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C
3 muscle MP:0005369 9.17 ADRA1A ADRA1B ADRA1D ADRA2B ADRB1 ADRB2

Drugs & Therapeutics for Prostatic Adenoma

Drugs for Prostatic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
2
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
3
Saw palmetto Approved, Experimental, Investigational Phase 4
4
Silodosin Approved Phase 4 160970-54-7
5
Finasteride Approved Phase 4 98319-26-7 57363
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
carbamide peroxide Approved Phase 4 124-43-6
8
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
9
Methyltestosterone Approved Phase 4 58-18-4 6010
10
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
11
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
12
Testosterone enanthate Approved Phase 4 315-37-7 9416
13
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
14
Tranexamic Acid Approved Phase 4 1197-18-8 5526
15
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
16
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
19
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
20
Mirabegron Approved Phase 4 223673-61-8 9865528
21
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
22
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Cimetropium Experimental, Investigational Phase 4 150521-16-7
27 Naftopidil Investigational Phase 4 57149-07-2
28
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
29
Fibrinolysin Investigational Phase 4 9004-09-5
30 Anticonvulsants Phase 4
31 Autonomic Agents Phase 4
32 Cola Phase 4
33 Bromides Phase 4
34 Antiemetics Phase 4
35 Gastrointestinal Agents Phase 4
36 Butylscopolammonium Bromide Phase 4
37 Mydriatics Phase 4
38 Anti-Infective Agents Phase 4
39 Saw palmetto extract Phase 4
40 Cholinergic Agents Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Calcium, Dietary Phase 4
43 calcium channel blockers Phase 4
44 Solifenacin succinate Phase 4 242478-38-2
45 Muscarinic Antagonists Phase 4
46 Cholinergic Antagonists Phase 4
47 Citrate Phase 4
48 Sildenafil Citrate Phase 4 171599-83-0
49 Endothelial Growth Factors Phase 4
50 Mitogens Phase 4

Interventional clinical trials:

(show top 50) (show all 536)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study) Unknown status NCT01218672 Phase 4
3 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
4 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
5 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
6 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
7 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
8 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
9 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
10 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
11 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
12 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
13 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
14 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
15 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
16 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
17 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
18 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
19 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Completed NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
20 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Completed NCT02034604 Phase 4 Naftofidil;Tamsulosin
21 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
22 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
23 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
24 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
25 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
26 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
27 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
28 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
29 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
30 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
31 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
32 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
33 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
34 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
35 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
36 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
37 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS
38 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
39 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
40 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
41 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
42 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
43 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
44 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
45 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
46 Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH Completed NCT00701779 Phase 4 Tamsulosin
47 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
48 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
49 The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility Completed NCT00836823 Phase 4 Alfuzosin
50 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem

Search NIH Clinical Center for Prostatic Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Cochrane evidence based reviews: prostatic hyperplasia

Genetic Tests for Prostatic Adenoma

Anatomical Context for Prostatic Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Prostatic Adenoma:

19
Prostate

MalaCards organs/tissues related to Prostatic Adenoma:

40
Prostate, Testes, Bone, Smooth Muscle, Kidney, Endothelial, Liver

Publications for Prostatic Adenoma

Articles related to Prostatic Adenoma:

(show top 50) (show all 14525)
# Title Authors PMID Year
1
[Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. 54 61
20169718 2009
2
[The experience in dutasteride use before transurethral prostatic resection for large adenoma]. 54 61
19054996 2008
3
[Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]. 54 61
18652016 2007
4
[Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)]. 54 61
17315721 2006
5
Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. 54 61
16686717 2006
6
[Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia]. 54 61
8928344 1996
7
Effect of digital rectal examination on plasma prostate-specific antigen (PSA). 54 61
8836791 1996
8
The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. 54 61
8851481 1995
9
Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). 54 61
8725044 1995
10
Predicted and actual change in serum PSA following prostatectomy for BPH. 54 61
7512298 1994
11
[Effect of rectal examination in patients with prostatic adenoma on concentration of prostatic specific antigen (PSA) in plasma]. 54 61
7526558 1993
12
Experience with prostate-specific antigen in prostatic carcinoma. 54 61
1718923 1991
13
[5-alpha reductase inhibitor in prostatic adenoma?]. 54 61
1705307 1990
14
Quantitative bidimentional and Doppler ultrasound assessment of the effect of a GnRH antagonist on canine prostatic hyperplasia. 61
31901534 2020
15
High serum concentration of estradiol may be a risk factor of prostate enlargement in aging male in China. 61
29912660 2020
16
Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL? 61
30862227 2020
17
Higher neural contribution underlying persistent lower urinary tract symptoms in men with Benign Prostatic Hyperplasia undergoing bladder outlet procedures. 61
31886434 2020
18
Letter to the editor regarding the article 'association between asthma and risk of benign prostatic hyperplasia: a retrospective population-based study'. 61
30879379 2020
19
Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo. 61
31756334 2020
20
The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate. 61
31487219 2020
21
Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. 61
31079189 2020
22
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers. 61
32017934 2020
23
[Comparison of 180 W Greenlight-XPS laser vaporisation and transurethral resection of the prostate: comfort for patients and healthcare staff in clinical routine practice]. 61
32018335 2020
24
Anatomical study of the prostatic urethra using vinyl polysiloxane casts. 61
31825529 2020
25
Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. 61
32029929 2020
26
Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis. 61
31801683 2020
27
State of the Art of Thulium Laser Enucleation and Vapoenucleation of the Prostate: A Systematic Review. 61
31726185 2020
28
Leptin promotes epithelial-mesenchymal transition in benign prostatic hyperplasia through downregulation of BAMBI. 61
31805276 2020
29
NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer. 61
31758937 2020
30
Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-κB signaling pathway. 61
31829321 2020
31
Prostate Benign Diseases. 61
32015291 2020
32
Regulation of microRNAs by rape bee pollen on benign prostate hyperplasia in rats. 61
31733069 2020
33
Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors. 61
32008083 2020
34
Assessment of the clinical efficacy of simultaneous transurethral resection of both bladder cancer and the prostate: a systematic review and meta-analysis. 61
32020826 2020
35
Stanniocalcin-1 protein expression profile and mechanisms in proliferation and cell death pathways in prostate cancer. 61
31816356 2020
36
Lasers in the surgical treatment of canine prostatic neoplasia and selected tumours of the male reproductive system. 61
32011789 2020
37
Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. 61
31734349 2020
38
Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice. 61
32016843 2020
39
Re: Alpha-Blockers with or without Phosphodiesterase Type 5 Inhibitor for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. 61
31710569 2020
40
The 11β-hydroxyandrostenedione pathway and C11-oxy C21 backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone. 61
31626910 2020
41
Critical Analysis of a Multicentric Experience with Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: Outcomes and Complications of Ten Years of Routine Clinical Practice. 61
32020749 2020
42
Smart spectrophotometric assessment of tamsulosin hydrochloride and tadalafil in their new pharmaceutical formulation for treatment of benign prostatic hyperplasia and erectile dysfunction. 61
31734571 2020
43
Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (< 80 cc) benign prostate hyperplasia: a prospective analysis. 61
30963229 2020
44
Holmium laser technologies versus photoselective greenlight vaporization for patients with benign prostatichyperplasia: a meta-analysis. 61
31939037 2020
45
Post-operative urinary retention after lower extremity arthroplasty and the peri-operative role of selective alpha-1 adrenergic blocking agents in adult male patients: a propensity-matched retrospective cohort study. 61
31641804 2020
46
Ultrasound-guided Morcellation During Difficult Holmium Laser Enucleation of the Prostate. 61
31589882 2020
47
Consequences of steroid-5α-reductase deficiency and inhibition in vertebrates. 61
31981690 2020
48
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). 61
31961963 2020
49
Transfusion rates after 800 Aquablation procedures using various haemostasis methods. 61
31901210 2020
50
GreenLight Photoselective Vaporization of the Prostate: One Laser for Different Prostate Sizes. 61
31617419 2020

Variations for Prostatic Adenoma

Expression for Prostatic Adenoma

Search GEO for disease gene expression data for Prostatic Adenoma.

Pathways for Prostatic Adenoma

Pathways related to Prostatic Adenoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 KLK3 CLIP3 ADRB3 ADRB2 ADRB1 ADRA2C
2
Show member pathways
13.41 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
3
Show member pathways
13.36 NUDT6 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B
4
Show member pathways
12.71 ADRB2 ADRB1 ADRA2B ADRA2A ADRA1B ADRA1A
5
Show member pathways
12.4 ADRB3 ADRB2 ADRB1 ADRA1D ADRA1B ADRA1A
6
Show member pathways
12.36 ADRB2 ADRA2C ADRA2B ADRA2A
7
Show member pathways
12.31 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
8
Show member pathways
12.14 ADRB3 ADRB2 ADRB1 ADRA1D ADRA1B ADRA1A
9
Show member pathways
12.03 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1B ADRA1A
10
Show member pathways
11.95 ADRB3 ADRB2 ADRB1 ADRA1D ADRA1B ADRA1A
11 11.92 ADRB3 ADRB2 ADRB1
12
Show member pathways
11.83 ADRA1D ADRA1B ADRA1A
13
Show member pathways
11.71 ADRA2C ADRA2B ADRA2A
14 11.54 ADRB3 ADRB2 ADRB1
15 11.51 ADRB2 ADRB1 ADRA2A ADRA1D
16 11.43 ADRB3 ADRB2 ADRB1
17
Show member pathways
11.32 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
18 11.12 ADRB1 ADRA1A
19 10.92 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D

GO Terms for Prostatic Adenoma

Cellular components related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.65 CLIP3 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B
2 integral component of plasma membrane GO:0005887 9.28 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A

Biological processes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 TAFA4 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B
2 G protein-coupled receptor signaling pathway GO:0007186 10.16 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
3 cell-cell signaling GO:0007267 9.95 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.87 ADRB3 ADRB2 ADRB1 ADRA2A
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 ADRA1D ADRA1B ADRA1A
6 platelet activation GO:0030168 9.81 ADRA2C ADRA2B ADRA2A
7 positive regulation of cold-induced thermogenesis GO:0120162 9.81 ADRB3 ADRB2 ADRB1
8 positive regulation of MAPK cascade GO:0043410 9.8 ADRB3 ADRB2 ADRA2C ADRA2B ADRA2A ADRA1B
9 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.79 ADRA1D ADRA1B ADRA1A
10 activation of adenylate cyclase activity GO:0007190 9.79 ADRB3 ADRB2 ADRB1
11 positive regulation of vasoconstriction GO:0045907 9.78 ADRA2C ADRA1D ADRA1B ADRA1A
12 activation of protein kinase B activity GO:0032148 9.77 ADRA2C ADRA2B ADRA2A
13 adrenergic receptor signaling pathway GO:0071875 9.76 ADRB3 ADRB2 ADRA2C ADRA2B ADRA2A ADRA1D
14 positive regulation of smooth muscle contraction GO:0045987 9.73 ADRA1D ADRA1B ADRA1A
15 regulation of vasoconstriction GO:0019229 9.72 ADRA2C ADRA2B ADRA2A ADRA1B ADRA1A
16 negative regulation of norepinephrine secretion GO:0010700 9.7 ADRA2C ADRA2B ADRA2A
17 receptor transactivation GO:0035624 9.67 ADRA2C ADRA2B ADRA2A
18 regulation of smooth muscle contraction GO:0006940 9.67 ADRB2 ADRA2C ADRA2B ADRA2A
19 regulation of sensory perception of pain GO:0051930 9.66 TAFA4 ADRA2C
20 brown fat cell differentiation GO:0050873 9.65 ADRB2 ADRB1
21 regulation of cardiac muscle contraction GO:0055117 9.65 ADRA1B ADRA1A
22 regulation of muscle contraction GO:0006937 9.64 ADRA1B ADRA1A
23 negative regulation of multicellular organism growth GO:0040015 9.63 ADRB2 ADRB1
24 negative regulation of epinephrine secretion GO:0032811 9.63 ADRA2C ADRA2B ADRA2A
25 diet induced thermogenesis GO:0002024 9.62 ADRB2 ADRB1
26 desensitization of G protein-coupled receptor signaling pathway by arrestin GO:0002032 9.61 ADRB3 ADRB2
27 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.61 ADRA1D ADRA1B ADRA1A
28 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.61 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
29 heat generation GO:0031649 9.59 ADRB2 ADRB1
30 positive regulation of the force of heart contraction by epinephrine-norepinephrine GO:0001997 9.58 ADRB1 ADRA1A
31 positive regulation of heart rate by epinephrine-norepinephrine GO:0001996 9.58 ADRB1 ADRA1A
32 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.58 ADRB3 ADRB2 ADRB1
33 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.28 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A

Molecular functions related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.97 ADRB3 ADRB2 ADRB1 ADRA2B ADRA2A ADRA1D
2 protein heterodimerization activity GO:0046982 9.85 ADRB1 ADRA2C ADRA2A ADRA1B ADRA1A
3 alpha2-adrenergic receptor activity GO:0004938 9.5 ADRA2C ADRA2B ADRA2A
4 norepinephrine binding GO:0051380 9.46 ADRB3 ADRB2 ADRB1 ADRA2A
5 alpha-2A adrenergic receptor binding GO:0031694 9.43 ADRB1 ADRA2C
6 alpha1-adrenergic receptor activity GO:0004937 9.43 ADRA1D ADRA1B ADRA1A
7 epinephrine binding GO:0051379 9.43 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
8 beta-adrenergic receptor activity GO:0004939 9.4 ADRB3 ADRB1
9 adrenergic receptor activity GO:0004935 9.28 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A

Sources for Prostatic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....